Baseline demographics and key outcomes of the patients
| Characteristics | Value |
| Mean age (SD) | 70.4 (12.3) |
| Gender n (%) | |
| Male | 49 (56.3) |
| Female | 38 (43.7) |
| Tumour histology n (%) | |
| Cholangiocarcinoma | 35 (40.2) |
| Metastases from other primaries | 31 (35.6) |
| Hepatocellular carcinoma | 9 (10.3) |
| Gallbladder adenocarcinoma | 7 (8.0) |
| Unknown histology | 5 (5.7) |
| Median CCI (IQR) | 9 (7 - 10) |
| American Society of Anaesthesiology score n (%) | |
| 1 | 0 |
| 2 | 9 (10.3) |
| 3 | 65 (74.7) |
| 4 | 13 (14.9) |
| 5 | 0 |
| Reason for inoperability n (%) | |
| Distant metastases | 63 (72.4) |
| Locally advanced disease | 16 (18.4) |
| Co-morbidities | 8 (9.2) |
| General anaesthesia n : Sedation n | 23 : 64 |
| Median serum bilirubin in μmol/L (IQR) | 267 (151 - 355) |
| Median serum albumin in g/L (IQR) | 27 (22 - 32) |
| White cell count ≥ 12 x 109/L n (%) | 16 (18.4) |
| Median CRP in mg/L (IQR) | 42 (23 - 83) |
| mGPS n (%) | |
| mGPS 0 | 13 (14.9) |
| mGPS 1 | 8 (9.2) |
| mGPS 2 | 66 (75.9) |
| Unilateral stenting intention | |
| Total | 46 |
| Success rate | 84.8% (39/46) |
| Bilateral stenting intention | |
| Total | 41 |
| Success rate | 80.5% (33/41) |
| Overall technical success | 82.8% (72/87) |
| Clinical success | 87.5% (49/56) |
| 30-day adverse event rate | 32.2% (28/87) |
| Cholangitis | 25.3% (22/87) |
| Pancreatitis | 3.8% (3/87) |
| Perforation | 1.1% (1/87) |
| Liver abscess | 1.1% (1/87) |
| GI bleed | 1.1% (1/87) |
| Aspiration pneumonia | 1.1% (1/87) |
| 30-day re-intervention rate | 11.5% (10/87) |
| Repeat ERCP | 8.0% (7/87) |
| PTC | 3.5% (3/87) |
| 30-day mortality rate | 25.3% (22/87) |
CCI, Charlson Comorbidity Index; CRP, C reactive protein; ERCP, endoscopic retrograde cholangiopancreatography; GI, gastrointestinal; mGPS, modified Glasgow Prognostic Score; PTC, percutaneous transhepatic cholangiogram.